Connect with us

Technology

Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-Inflammatory Peptide Therapeutic for Atopic Dermatitis

Published

on

NASHVILLE, June 28, 2023 /PRNewswire/ — Amytrx Therapeutics, an emerging pharmaceutical company specializing in innovative anti-inflammatory therapies, is pleased to announce the open enrollment for its highly anticipated Phase 2b clinical trial of a topical formulation of AMTX-100 CF3, a groundbreaking anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis. This milestone marks a significant step forward in the development of advanced treatment options for individuals affected by this chronic and debilitating skin condition.

The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of safety.

Atopic dermatitis, also known as eczema, affects millions of adults worldwide, causing intense itching, redness, and dry skin (1). Despite the availability of various treatment options, there remains an unmet need for more effective and safer therapies. With this topical formulation of AMTX-100 CF3, Amytrx Therapeutics aims to revolutionize the treatment landscape and offer hope to those living with atopic dermatitis.

The Phase 2b clinical trial will continue to build upon a recent trial that has evaluated the safety and efficacy of AMTX-100 CF3 in a larger cohort of adult patients that has shown favorable efficacy bypassing the need for rescue steroid treatment. This randomized, double-blind, placebo-controlled study will be conducted at 8-10 clinical sites across the country. This study is seeking 60 participants to generate a 1:1 ratio between placebo and active arms of the study. The trial’s primary endpoints include improvement in disease severity, reduction in symptoms, and assessment of treatment safety.

This clinical trial will include a 28-day treatment period with twice daily treatment and a 2-week follow-up assessment post-treatment to determine therapeutic efficacy. In addition, participants will receive a topical emollient 2-weeks prior to trial to exclude participants who may be impacted by a placebo effect. Precision medicine techniques will also be used to assess changes in the expression of genes involved in inflammation.

“We are thrilled to initiate the open enrollment for our Phase 2b clinical trial of AMTX-100 CF3,” said Dr. Matthew A. Gonda, CEO of Amytrx Therapeutics. “At Amytrx, we are committed to developing innovative therapies that can make a meaningful difference in the lives of patients. This trial represents a crucial step towards bringing a safe and targeted treatment option to adults suffering from atopic dermatitis, in addition to other chronic inflammatory skin diseases such as psoriasis, vitiligo, lupus, graft vs. host, and more.”

Amytrx Therapeutics has invested years of research and development into the creation of AMTX-100 CF3. This unique topical formulation of their anti-inflammatory peptide has shown promising results in preclinical and clinical studies. AMTX-100 CF3 utilizes a novel untapped intracellular target to control inflammation. The company believes that AMTX-100 CF3 has the potential to provide durable relief, enhance quality of life, and minimize the burden of this chronic condition with a revolutionary approach that interacts with a key checkpoint in the initiation of inflammation.

The open enrollment for the Phase 2b clinical trial of AMTX-100 CF3 is now underway. Eligible adults interested in participating or learning more about the trial are encouraged to visit the ClinicalTrials.Gov listing # NCT04313400 or visit Amytrx Therapeutics’ website at www.amytrx.com. The company welcomes collaboration with research institutions that wish to contribute to advancing the knowledge and treatment of other inflammatory skin disorders.

The current topical formulation of AMTX-100 CF3 being studied in the Phase 2b clinical trial provides an example of the various formulations available for novel anti-inflammatory peptide AMTX-100. Amytrx Therapeutics is actively exploring other delivery methods to cater to the diverse needs of patients across a variety of inflammatory diseases. These formulations include oral, injectable, nasal spray, and other options. This comprehensive approach underscores Amytrx Therapeutics’ commitment to developing a range of therapeutic options that can effectively target inflammation and provide additional treatment strategies.

About Amytrx Therapeutics

Amytrx Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the first anti-inflammatory human peptide platform (AMTX-100) yielding the potential for vastly optimized, cutting-edge therapies that safely alter the course of chronic inflammation and metabolic dysfunction to prevent and treat some of the world’s most debilitating diseases. For further information, please visit www.amytrx.com. 

Kapur, S., Watson, W., & Carr, S. (2018). Atopic dermatitis. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 14(Suppl 2), 52. https://doi.org/10.1186/s13223-018-0281-6

View original content to download multimedia:https://www.prnewswire.com/news-releases/amytrx-therapeutics-announces-open-enrollment-for-phase-2b-clinical-trial-of-amtx-100-cf3-a-promising-anti-inflammatory-peptide-therapeutic-for-atopic-dermatitis-301866172.html

SOURCE Amytrx Therapeutics

Continue Reading

Technology

2026 Canton Fair Design Award Winners Showcase China’s Innovation Strength

Published

on

By

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ — As the 140th Canton Fair opens, the winners of the 2026 Canton Fair Design Award (CF Award) have also been announced. Winning products are now on display in Area D of the Canton Fair Complex, offering visitors a closer look at some of the latest advances in Chinese manufacturing and industrial design.

Among this year’s top honorees, a domestically developed high-performance sport motorcycle and an intelligent navigation capsule robot gastric endoscopy system received the Best of the Best Award, the competition’s highest recognition.

The Canton Fair also enhanced the visitor experience with a themed showcase area within the award exhibition. Built around four application-oriented concepts, namely Outdoor Pleasure, Smart Living, Cozy Home and Kitchen Elegance, the immersive displays demonstrate how innovative designs can be integrated into everyday life, helping visitors better understand the practical value behind these award-winning products.

This year, 4,218 products from 2,112 companies competed for the award. Following multiple rounds of evaluation, 222 products from 174 companies were selected.

The award-winning products reflect several key trends shaping the next stage of Chinese manufacturing. Innovation remains a defining theme, with breakthrough technologies ranging from upper limb motor function assistance and enhancement system to exoskeleton robots, underscoring the growing momentum of high-end manufacturing.

Meanwhile, intelligent technologies continue to gain traction across industries. Smart products account for more than 30% of this year’s winners, with AI-powered glasses, intelligent conference terminals and smart healthcare devices extending AI applications across home, office, medical and outdoor environments.

Sustainability is also becoming increasingly embedded throughout the product lifecycle. Green products represent over 40% of the winning entries, while innovations such as integrated energy-saving panels and sugarcane paper demonstrate how environmentally conscious practices are being incorporated into product design, materials selection and manufacturing processes.

Established in 2013, the Canton Fair Design Award is widely regarded as a benchmark for design innovation in China’s foreign trade sector. The award recognizes products that combine design excellence with commercial value, promoting the transformation and upgrading of Chinese manufacturing and supporting high-quality trade development. Entries are evaluated across five dimensions: innovation, quality, functionality, aesthetics and sustainability.

For more convenient attendance, please click here for pre-registration:
https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/2026-canton-fair-design-award-winners-showcase-chinas-innovation-strength-302911954.html

SOURCE Canton Fair

Continue Reading

Technology

InstaMall Launches Same-Day Fashion Delivery Experience, Bringing 80+ Brands to Shoppers’ Doors in Miami

Published

on

By

First-of-its-kind shopping app pairs artificial intelligence with same-day delivery, bringing luxury
and contemporary brands directly to customers’ doorsteps 

Featured luxury and contemporary brands include AllSaints, John Varvatos and Aritzia

MIAMI, Oct. 19, 2026 /PRNewswire/ — InstaMall, a first-of-its-kind shopping app offering same-day delivery and access to real-time inventory across luxury and contemporary fashion, launches today in Miami, Florida. Now available via iOS and Android, InstaMall provides access to more than 80 contemporary and luxury fashion brands across Miami’s five premier retail clusters, including Balmain, Louis Vuitton, Bottega Veneta, Ganni, Coach, Diesel, Reformation, Aritzia, Cult Gaia, Prada and more. InstaMall will add more brands within the app in the coming weeks and seasons. 

Sitting at the intersection of fashion, technology and commerce, InstaMall brings inspiration and purchase together through a more dynamic way to discover and shop for fashion. The experience combines access to luxury and contemporary brands with the convenience of same-day delivery, bringing the speed customers have come to expect across categories like food and groceries to fashion while maintaining the brand experience retailers and shoppers expect.

Within the app, customers will have access to InstaMall’s AI-powered stylist and virtual try-on features, making it easier to browse, discover and shop styles online. InstaMall’s AI Stylist serves as an intelligent shopping assistant that responds to customers’ preferences in real time. Customers can use the AI Stylist to receive product recommendations, build outfits, ask questions and discover new styles, while its virtual try-on feature allows them to visualize select items on themselves before making a purchase.

“InstaMall was founded on the belief that the convenience customers have come to expect from same-day delivery should extend to the way they shop for fashion,” said Elliot Aboud, Founder and CEO of InstaMall. “As fashion and technology continue to evolve together, we saw an opportunity to create a more seamless shopping experience that brings customers closer to the brands they love, combining a curated assortment, AI-powered styling and virtual try-on with the ease and convenience of same-day delivery.”

Prior to founding InstaMall, Elliot Aboud helped build the Aroma360 and Hotel Collection brands, overseeing the launch of the first retail store and expanding the retail footprint to more than 30 stores across the United States and two in Dubai. InstaMall is bringing fashion and luxury to the next generation with its seamless shopping experience and wide selection of brands.

Customers can download InstaMall through the Apple App Store or Google Play, or by going to instamall.co.

About InstaMall 

InstaMall is a same-day fashion shopping and discovery app reimagining how consumers shop for luxury and contemporary brands. Sitting at the intersection of fashion, technology and commerce, InstaMall brings inspiration and purchase together in an experience that gives consumers a more dynamic way to discover and shop. Where on-demand delivery has long existed for categories like food and groceries, InstaMall brings that same convenience to luxury fashion for the first time, delivering the same day without compromising the brand experience fashion retailers and their customers expect. The company launched publicly in Miami on October 16, 2026, and plans to expand nationally. For more information, please visit instamall.co.

View original content to download multimedia:https://www.prnewswire.com/news-releases/instamall-launches-same-day-fashion-delivery-experience-bringing-80-brands-to-shoppers-doors-in-miami-302911889.html

SOURCE InstaMall

Continue Reading

Technology

PTC to Announce Fourth Fiscal Quarter and Full Year 2026 Results on Wednesday, November 4, 2026

Published

on

By

BOSTON, Oct. 19, 2026 /PRNewswire/ — PTC (NASDAQ: PTC) will release its fiscal 2026 fourth quarter and full year results on Wednesday, November 4th after the stock market closes. As previously announced on October 5th, 2026, PTC entered into a definitive agreement to be acquired by Schneider Electric. In light of the pending transaction, PTC is suspending quarterly earnings conference calls and is no longer providing quarterly or annual guidance.

The earnings press release and accompanying financial data tables will be accessible on the Investor Relations section of the company’s website at PTC Investor Relations.

About

PTC (NASDAQ: PTC) is a global software company that enables manufacturers and product companies to digitally transform how they design, manufacture, and service the physical products the world relies on. Headquartered in Boston, Massachusetts, PTC employs over 7,000 people and supports more than 30,000 customers globally. For more information, please visit www.ptc.com.

Investors

Michael Maguire
mmaguire@ptc.com
investor@ptc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-to-announce-fourth-fiscal-quarter-and-full-year-2026-results-on-wednesday-november-4-2026-302912229.html

SOURCE PTC Inc.

Continue Reading

Trending